Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BMRN NASDAQ:CCXI NASDAQ:EXAS NASDAQ:NBIX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMRNBioMarin Pharmaceutical$54.09-3.3%$58.02$52.93▼$85.00$10.74B0.351.66 million shs1.93 million shsCCXIChemoCentryx$51.99$51.95$14.95▼$52.00$3.71B1.221.68 million shs113 shsEXASExact Sciences$53.94-3.7%$48.86$38.81▼$72.83$10.60B1.052.84 million shs2.32 million shsNBIXNeurocrine Biosciences$141.87-1.2%$134.13$84.23▼$154.61$14.24B0.28702,053 shs485,690 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMRNBioMarin Pharmaceutical0.00%-6.37%-6.74%-3.79%-36.20%CCXIChemoCentryx0.00%0.00%0.00%0.00%0.00%EXASExact Sciences0.00%+0.24%+19.89%+0.78%-15.88%NBIXNeurocrine Biosciences0.00%-1.55%+8.04%+14.05%+16.79%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMRNBioMarin Pharmaceutical$54.09-3.3%$58.02$52.93▼$85.00$10.74B0.351.66 million shs1.93 million shsCCXIChemoCentryx$51.99$51.95$14.95▼$52.00$3.71B1.221.68 million shs113 shsEXASExact Sciences$53.94-3.7%$48.86$38.81▼$72.83$10.60B1.052.84 million shs2.32 million shsNBIXNeurocrine Biosciences$141.87-1.2%$134.13$84.23▼$154.61$14.24B0.28702,053 shs485,690 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMRNBioMarin Pharmaceutical0.00%-6.37%-6.74%-3.79%-36.20%CCXIChemoCentryx0.00%0.00%0.00%0.00%0.00%EXASExact Sciences0.00%+0.24%+19.89%+0.78%-15.88%NBIXNeurocrine Biosciences0.00%-1.55%+8.04%+14.05%+16.79%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBMRNBioMarin Pharmaceutical 2.69Moderate Buy$92.0470.16% UpsideCCXIChemoCentryx 0.00N/AN/AN/AEXASExact Sciences 2.88Moderate Buy$68.0526.16% UpsideNBIXNeurocrine Biosciences 2.86Moderate Buy$160.0012.78% UpsideCurrent Analyst Ratings BreakdownLatest CCXI, NBIX, BMRN, and EXAS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/11/2025EXASExact SciencesCraig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$65.00 ➝ $85.009/8/2025BMRNBioMarin PharmaceuticalHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$60.009/5/2025NBIXNeurocrine BiosciencesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$144.00 ➝ $149.009/5/2025NBIXNeurocrine BiosciencesMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$158.00 ➝ $163.009/4/2025EXASExact SciencesZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold9/3/2025BMRNBioMarin PharmaceuticalRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$85.008/13/2025BMRNBioMarin PharmaceuticalZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/12/2025EXASExact SciencesBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$65.00 ➝ $60.008/11/2025EXASExact SciencesPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$70.00 ➝ $60.008/8/2025EXASExact SciencesEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$68.00 ➝ $64.008/7/2025EXASExact SciencesCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 9/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBMRNBioMarin Pharmaceutical$3.06B3.39$3.14 per share17.22$29.69 per share1.82CCXIChemoCentryx$32.22M115.14N/AN/A$4.09 per share12.71EXASExact Sciences$2.76B3.70$5.43 per share9.94$12.98 per share4.16NBIXNeurocrine Biosciences$2.36B5.97$3.34 per share42.49$25.58 per share5.55Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBMRNBioMarin Pharmaceutical$426.86M$3.3716.0512.410.7121.45%12.59%10.13%11/4/2025 (Estimated)CCXIChemoCentryx-$131.76M-$1.89N/AN/AN/A-357.01%-48.52%-30.59%N/AEXASExact Sciences-$1.03B-$5.43N/A107.885.73-34.19%-1.75%-0.76%11/4/2025 (Estimated)NBIXNeurocrine Biosciences$341.30M$3.3841.9721.931.0313.88%13.22%9.39%10/29/2025 (Estimated)Latest CCXI, NBIX, BMRN, and EXAS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025EXASExact Sciences-$0.02$0.22+$0.24-$0.01$774.43 million$811.09 million7/30/2025Q2 2025NBIXNeurocrine Biosciences$0.98$1.06+$0.08$1.06$653.09 million$687.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBMRNBioMarin PharmaceuticalN/AN/AN/AN/AN/ACCXIChemoCentryxN/AN/AN/AN/AN/AEXASExact SciencesN/AN/AN/AN/AN/ANBIXNeurocrine BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBMRNBioMarin Pharmaceutical0.105.563.60CCXIChemoCentryx0.024.544.47EXASExact Sciences0.942.892.56NBIXNeurocrine BiosciencesN/A3.203.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBMRNBioMarin Pharmaceutical98.71%CCXIChemoCentryx81.09%EXASExact Sciences88.82%NBIXNeurocrine Biosciences92.59%Insider OwnershipCompanyInsider OwnershipBMRNBioMarin Pharmaceutical0.85%CCXIChemoCentryx8.30%EXASExact Sciences1.20%NBIXNeurocrine Biosciences4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBMRNBioMarin Pharmaceutical3,040192.02 million190.38 millionOptionableCCXIChemoCentryx17871.36 million65.43 millionOptionableEXASExact Sciences7,000189.32 million187.05 millionOptionableNBIXNeurocrine Biosciences1,80099.18 million94.42 millionOptionableCCXI, NBIX, BMRN, and EXAS HeadlinesRecent News About These CompaniesPlato Investment Management Ltd Has $255,000 Stock Holdings in Neurocrine Biosciences, Inc. $NBIXSeptember 14 at 4:28 AM | marketbeat.comWoodline Partners LP Invests $14.70 Million in Neurocrine Biosciences, Inc. $NBIXSeptember 13 at 4:37 AM | marketbeat.comGreat Lakes Advisors LLC Has $3.54 Million Stock Position in Neurocrine Biosciences, Inc. $NBIXSeptember 13 at 4:19 AM | marketbeat.comVident Advisory LLC Invests $202,000 in Neurocrine Biosciences, Inc. $NBIXSeptember 13 at 3:13 AM | marketbeat.comUnited Services Automobile Association Makes New $741,000 Investment in Neurocrine Biosciences, Inc. $NBIXSeptember 11 at 5:29 AM | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Short Interest Up 39.6% in AugustSeptember 10, 2025 | marketbeat.comTeza Capital Management LLC Sells 12,560 Shares of Neurocrine Biosciences, Inc. $NBIXSeptember 10, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Acquires 21,726 Shares of Neurocrine Biosciences, Inc. $NBIXSeptember 10, 2025 | marketbeat.comNeurocrine Biosciences, Inc. $NBIX Shares Sold by AmundiSeptember 10, 2025 | marketbeat.comNeurocrine Biosciences, Inc. (NBIX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 9, 2025 | seekingalpha.comParkman Healthcare Partners LLC Has $18.62 Million Stock Position in Neurocrine Biosciences, Inc. $NBIXSeptember 8, 2025 | marketbeat.comNeurocrine Biosciences, Inc. $NBIX Shares Sold by EFG Asset Management North America Corp.September 7, 2025 | marketbeat.comAQR Capital Management LLC Sells 822,261 Shares of Neurocrine Biosciences, Inc. $NBIXSeptember 7, 2025 | marketbeat.comNeurocrine Biosciences, Inc. $NBIX Shares Sold by Alyeska Investment Group L.P.September 7, 2025 | marketbeat.comBaird Financial Group Inc. Boosts Holdings in Neurocrine Biosciences, Inc. $NBIXSeptember 6, 2025 | marketbeat.comBreaking Down Neurocrine Biosciences: 12 Analysts Share Their ViewsSeptember 5, 2025 | benzinga.comFederation des caisses Desjardins du Quebec Cuts Holdings in Neurocrine Biosciences, Inc. $NBIXSeptember 5, 2025 | marketbeat.comPDT Partners LLC Has $2.04 Million Stake in Neurocrine Biosciences, Inc. $NBIXSeptember 5, 2025 | marketbeat.comPalo Alto Investors LP Acquires New Position in Neurocrine Biosciences, Inc. $NBIXSeptember 4, 2025 | marketbeat.comNeurocrine Biosciences, Inc. (NBIX) Presents At Cantor Global Healthcare Conference 2025 TranscriptSeptember 3, 2025 | seekingalpha.comBraidwell LP Has $131.83 Million Position in Neurocrine Biosciences, Inc. $NBIXSeptember 3, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCCXI, NBIX, BMRN, and EXAS Company DescriptionsBioMarin Pharmaceutical NASDAQ:BMRN$54.09 -1.82 (-3.26%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$54.50 +0.41 (+0.76%) As of 09/12/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.ChemoCentryx NASDAQ:CCXIChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.Exact Sciences NASDAQ:EXAS$53.94 -2.06 (-3.68%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$52.14 -1.80 (-3.34%) As of 09/12/2025 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.Neurocrine Biosciences NASDAQ:NBIX$141.87 -1.73 (-1.20%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$140.70 -1.17 (-0.82%) As of 09/12/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
